Market News & Trends
Mitsubishi Chemical Advanced Materials to Become Climate Neutral by 2023 & Targets Climate Positivity by 2030
Mitsubishi Chemical Advanced Materials AG (MCAM), a leading global manufacturer of high-performance materials, is proud to announce its goal to achieve climate positivity in its…
Noxopharm Phase 1 Clinical Trial Shows Anti-Inflammatory Response in COVID-19 Patients
Noxopharm has released preliminary top-line data from its NOXCOVID Phase I clinical trial testing the suitability of idronoxil (Veyonda®), a TBK1 (TANK-binding kinase 1) inhibitor,…
BioPlx Announces Focus on Developing Cure for Antibiotic-Resistant Bacteria
Antimicrobial Resistance (AMR) is one of the greatest threats to society, human and animal health, and economic prosperity. Those are the unequivocal words regarding the…
Recipharm Launches New Laboratory to Expand Analytical Services Offering
Global contract development and manufacturing organisation (CDMO), Recipharm, has announced the completion of a new analytical laboratory at its facility in Bengaluru, India. The new…
Persica Pharmaceuticals Has Completed the First Stage of its Clinical Trial on Unique Injectable to Treat Chronic Lower Back Pain
Persica Pharmaceuticals Ltd recently announced it has successfully completed the first stage of a Phase Ib clinical trial to evaluate the safety, tolerability, and pharmacokinetics…
AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients With Severe Exocrine Pancreatic Insufficiency
AzurRx BioPharma recently announced positive topline results from its Phase 2 Combination Trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme…
Solaris Pharma Receives Approval for First Generic Version of Clindagel
Solaris Pharma Corporation recently announced the company has received an abbreviated new drug application (ANDA) approval from the US FDA for the first generic version…
NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody
NGM Biopharmaceuticals, Inc. recently disclosed its fourth oncology development candidate, NGM831, an antagonist antibody designed to block the interaction of ILT3 with fibronectin, as well…
Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome
Zealand Pharma A/S recently announced dose administration for the first subject in the Phase 3b trial, EASE-SBS 4, evaluating glepaglutide, the company’s long-acting GLP-2 analog,…
Assembly Bio Selects Fourth HBV Core Inhibitor Candidate for Advancement Into Clinical Development
Assembly Biosciences, Inc. recently announced it has selected a fourth core inhibitor candidate, ABI-4334 (4334), that has been optimized for potency, to advance into clinical…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….